Eli Lilly to stop developing schizophrenia drug
Aug 29 (Reuters) - Eli Lilly and Co said it would stop developing an experimental schizophrenia drug after a recent analysis showed that a late-stage trial on the drug was likely to fail.
Lilly said that an independent futility analysis concluded the second late-stage study on the drug was unlikely to meet the main goal of the trial.
Additionally, another mid-stage trial, which was testing the drug -- pomaglumetad methionil, or mGlu2/3 -- as an adjunctive treatment with atypical antipsychotics, also failed to meet the main study goal.
- Judge rejects strict limits on U.S. nurse who treated Ebola patients |
- Test flight of Virgin Galactic spaceship ends in fatal crash in California
- Suspect in Pennsylvania police ambush denied bail |
- Dow, S&P 500 end at record highs; BoJ move adds fuel to rally |
- Judge issues order enforcing Ebola isolation of defiant Maine nurse